Pharmaceutical formulations, processes for preparation, and methods of use
AU2016253544A1
Sns-595 and methods of using the same
BR112018008025A2
heterocyclic pdk1 inhibitors for use in cancer treatment
AU2016210659A1
METHODS OF USING (+)-1,4-DIHYDRO-7-[(3s,4s)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION THERAPY
AU2016210657A1
Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
AU2015246121A1
Stable sns-595 compositions and methods of preparation
AU2014277779A1
METHODS OF USING (+)-1,4-DIHYDRO-7-[(3s,4s)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION THERAPY
US2014205680A1
Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
AU2013219242A1
Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
NZ743260A
Bipiperidine-2-one compounds for the preparation of pyrimidinyl tyrosine kinase inhibitors
NZ737572A
Intermediate compounds for the preparation of bipiperidine-2-one compounds
AU2013202641A1
Stable sns-595 compositions and methods of preparation
TW201120037A
Compounds and methods for treatment of cancer
CN102596948A
Stable SNS-595 compositions and methods of preparation
SG173855A1
Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity
SG10201504789RA
Method Of Preparing (+)-1,4-Dihydro-7-[(3s,4s)-3methoxy-4-(Methylamino)-1-Pyrrolidinyl]-4-Oxo-1-(2-Thiazolyl)-1,8-Naphthyridine-3-Carboxylic Acid
EP2257637A1
Methods of chemotype evolution
EP2265618A2
Aurora kinase inhibitors
WO2009102937A1
Processes for the preparation of carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s
EP2649997A1
(+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome
